Beryl Drugs Ltd Upgraded to Hold by MarketsMOJO on Improved Technicals and Valuation

Technical Trend Upgrade Spurs Rating Change

The primary catalyst for the upgrade was a marked improvement in the technical grade, which shifted from mildly bullish to bullish. Key technical indicators underpinning this change include a bullish Moving Average Convergence Divergence (MACD) on the weekly chart and a bullish stance on Bollinger Bands weekly readings. Daily moving averages have also turned bullish, reinforcing positive momentum in the stock price.

Other technical signals such as the KST (Know Sure Thing) indicator are bullish on a weekly basis and mildly bullish monthly, while the Relative Strength Index (RSI) remains neutral with no clear signal. The Dow Theory, however, shows no definitive trend on weekly or monthly timeframes, suggesting some caution remains among market participants.

These technical improvements have coincided with a modest day change of +0.89% to close at ₹23.90, with the stock trading comfortably above its 52-week low of ₹15.92 but still below its 52-week high of ₹27.60. The recent price action indicates a potential base formation that could support further gains if positive momentum sustains.

Valuation Remains a Strong Positive

Beryl Drugs’ valuation metrics have also played a significant role in the upgrade. The company boasts a very attractive Enterprise Value to Capital Employed (EV/CE) ratio of 1.2, signalling that the stock is trading at a discount relative to the capital it employs. This is particularly notable given the company’s micro-cap status, where valuation inefficiencies are more common.

Moreover, the stock trades at a discount compared to its peers’ average historical valuations within the Pharmaceuticals & Biotechnology sector. This relative undervaluation provides a margin of safety for investors and supports the Hold rating despite some fundamental weaknesses.

The Return on Capital Employed (ROCE) stands at 7.6% for the latest period, slightly below the company’s five-year average of 8.19%, but still indicative of moderate capital efficiency. The Price/Earnings to Growth (PEG) ratio is exceptionally low at 0.1, reflecting the stock’s modest price relative to its earnings growth potential, which is a positive sign for value-oriented investors.

Financial Trend: Mixed Signals Amid Flat Quarterly Performance

Financially, Beryl Drugs reported flat performance in the first quarter of FY26-27, with no significant growth in revenues or profits during this period. This stagnation tempers enthusiasm but does not detract from the company’s longer-term growth trajectory.

Over the past year, the stock has generated a return of 4.64%, outperforming the Sensex which declined by 9.40% over the same period. Additionally, the company’s profits have risen by a robust 39% year-on-year, signalling operational improvements despite flat quarterly sales.

However, the company’s long-term fundamentals remain weak. Net sales have grown at a modest compound annual growth rate (CAGR) of 6.33% over the last five years, while operating profit has increased at an even slower rate of 5.39%. The average EBIT to interest coverage ratio is a concerning 0.92, indicating the company’s ability to service debt is limited and could pose risks if earnings falter.

Comparative Returns Highlight Long-Term Challenges

When viewed over longer horizons, Beryl Drugs’ returns have been mixed. While the stock has delivered an impressive 106.39% return over five years, significantly outperforming the Sensex’s 26.87% gain, its 10-year return of 41.00% lags behind the Sensex’s 162.59%. This disparity underscores the company’s inconsistent performance and the challenges it faces in sustaining growth over extended periods.

Shorter-term returns also show volatility, with a one-month gain of 4.82% contrasting with a one-week loss of 0.38%, reflecting the stock’s sensitivity to market sentiment and sector dynamics.

Shareholding and Market Capitalisation Context

Beryl Drugs remains a micro-cap stock with a market capitalisation grade reflecting its relatively small size. The majority of its shares are held by non-institutional investors, which can contribute to higher volatility and less liquidity compared to larger, institutionally backed companies.

This ownership structure may also influence the stock’s price movements and investor perception, as institutional investors often provide stability and confidence in a company’s prospects.

Summary: Balanced Outlook with Cautious Optimism

The upgrade of Beryl Drugs Ltd’s rating from Sell to Hold reflects a nuanced assessment of its current position. Improved technical indicators suggest a positive shift in market sentiment, while valuation metrics indicate the stock is attractively priced relative to its capital employed and sector peers.

However, the company’s flat recent financial performance, weak long-term growth rates, and limited debt servicing capacity temper enthusiasm. Investors should weigh these factors carefully, recognising that while the stock may offer value and momentum in the near term, fundamental challenges remain.

For those considering exposure to the Pharmaceuticals & Biotechnology sector, Beryl Drugs represents a micro-cap option with potential upside but also inherent risks. The Hold rating advises a watchful stance, awaiting clearer signs of sustained financial improvement before committing more aggressively.

Technical and Fundamental Metrics at a Glance:

• Mojo Score: 54.0 (Hold), upgraded from Sell on 21 Sep 2026
• Technical Trend: Upgraded from mildly bullish to bullish
• ROCE: 7.6% (slightly below 5-year average of 8.19%)
• EV/Capital Employed: 1.2 (very attractive valuation)
• PEG Ratio: 0.1 (indicating undervaluation relative to growth)
• Profit Growth (YoY): +39%
• Net Sales CAGR (5 years): 6.33%
• Operating Profit CAGR (5 years): 5.39%
• EBIT to Interest Coverage Ratio: 0.92 (weak debt servicing)
• Market Cap Grade: Micro-cap
• Majority Shareholders: Non-institutional

Investment Implications

Investors should consider Beryl Drugs as a stock with improving technical momentum and attractive valuation but with fundamental headwinds that warrant caution. The Hold rating suggests monitoring upcoming quarterly results and sector developments closely before increasing exposure.

Looking Ahead

Future upgrades to the rating will likely depend on the company demonstrating consistent revenue growth, improved profitability, and stronger debt servicing capabilities. Continued positive technical signals may also support a more bullish stance if confirmed by fundamental progress.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →